Aura Biosciences
- Market cap
- 670.45M
- P/E (TTM)i
- -3.74
- P/Bi
- 2.13
- EPSi
- -1.76
- Div yieldi
- 0.00%
- 52W posi
- 36%
Anonymous reader poll. Unscientific, not investment advice.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.
- Founded
- 2007
- CEO
- Ms. Natalie C. Holles
- Employees
- 113
- Headquarters
- Boston, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- aurabiosciences.com
Company profile
- Exchange
- US
- Symbol
- AURA
- Market-cap rank
- #3544
- Listing date
- 2021-10-29
- Market cap
- 670.45M
- Float cap
- 482.57M
- Shares out
- 103.70M
- Float shares
- 74.64M
Sectors & themes
Quote time 2026-10-08 10:00:20 · For reference only, not investment advice and not tailored to your situation.